Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT60Q8D)

• DTT Name: Orexin receptor type 1 (HCRTR1) DTT Info
• Gene Name: HCRTR1

Molecule-Related Drug & Molecule List

3 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JNJ-61393215	DME2S4D	Major depressive disorder	6A70.3	Phase 2	[1]
SB-649868	DMYLBOU	Insomnia	7A00-7A0Z	Phase 2	[2]
AZD4041	DMEPQI4	Opioid use disorder	6C43.2Z	Phase 1	[3]

33 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1,2-diamino cyclopentane-based derivative 1	DMNH8GW	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 10	DM3ZF95	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 11	DMPZECW	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 12	DMWV53X	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 13	DM10UX4	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 14	DMTZDUV	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 15	DMBY65W	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 16	DMHEX1Q	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 17	DMBC9UK	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 18	DMCNQAF	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 19	DMCBPI4	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 2	DM7RG5I	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 20	DM9PHIK	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 21	DM5Y1DC	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 22	DMXRLI6	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 23	DM0HIQU	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 24	DMC26MT	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 25	DMEW0AT	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 26	DMTFG4J	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 27	DM5LQJW	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 29	DM5FVH0	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 3	DM143OK	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 30	DMZ4NJQ	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 31	DMVZ5EP	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 32	DMQX8SD	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 33	DMBOLSU	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 34	DMVHL3W	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 4	DMFBPSX	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 5	DMCP15K	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 6	DMJ4ACP	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 7	DMHIV24	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 8	DM7JX8U	N. A.	N. A.	Patented	[4]
1,2-diamino cyclopentane-based derivative 9	DM7I8ZV	N. A.	N. A.	Patented	[4]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Almorexant	DMQALR5	Insomnia	7A00-7A0Z	Terminated	[5]

6 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
orexin-B	DM0XT69	Discovery agent	N.A.	Investigative	[6]
PMID15261275C1	DMFI4J6	Discovery agent	N.A.	Investigative	[7]
SB-334867	DMDZKWJ	Discovery agent	N.A.	Investigative	[5]
SB-408124	DMB8XZP	Discovery agent	N.A.	Investigative	[5]
SB-410220	DMQLHE8	Discovery agent	N.A.	Investigative	[8]
[3H]SB-674042	DMO9L38	Discovery agent	N.A.	Investigative	[9]

References

• [1] Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans. Transl Psychiatry. 2020 Sep 7;10(1):308.
• [2] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [3] Clinical pipeline report, company report or official report of AstraZeneca
• [4] Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
• [5] Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison ... Mol Pharmacol. 2009 Sep;76(3):618-31.
• [6] Agonist ligand discrimination by the two orexin receptors depends on the expression system. Neurosci Lett. 2011 Apr 20;494(1):57-60.
• [7] Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4225-9.
• [8] Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol. 2004 Jan;141(2):340-6.
• [9] Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA). Mol Pharmacol. 2010 Jul;78(1):81-93.